Could an asthma pill tame tough eczema?

NCT ID NCT07297602

Recruiting now Disease control Sponsor: Nora Mohamed Abdelrazik Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study is testing whether an oral medication called roflumilast (already used for other conditions) can help people aged 12 and older with moderate-to-severe atopic dermatitis (eczema). 36 participants will take a daily pill for 12 weeks. The study measures changes in eczema severity and tracks side effects. It is an early, small trial without a placebo group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral roflumilast (a pill, brand name Daxas)
What this could lead to: If it works, this could point toward a new oral treatment option for moderate-to-severe eczema.
What could go wrong: This is a very small, early pilot study with no placebo group. Results may not be conclusive, and side effects like diarrhea, nausea, or headache are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Mansoura University Hospital
RECRUITING

Al Mansurah, Dakahlia Governorate, 35511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.